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doi:10.1016/j.febslet.2006.08.001Prof. Varda Rotter completed both her B.Sc. and M.Sc. studies
at Bar-Ilan University (Israel). A PhD (1976) and a ﬁrst post-
doc soon followed at the Weizmann Institute of Science (Is-
rael). She then moved to MIT (Boston) for a second post-doc
with David Baltimore, before returning to the Weizmann Insti-
tute, where she works to this day. She has been awarded several
prizes in recognition of her scientiﬁc achievements, including
the prestigious Israeli EMET prize. Varda serves as Chairman
of the Department of Molecular Cell Biology and heads the
Women’s Health Centre at theWeizmann Institute. Varda edits
papers for FEBS Letters involving the role of the p53 tumor
suppressor protein in regulating cell cycle, growth and death.What does your lab do?
You could say that I am a single-gene researcher! We are inter-
ested in all facets of the p53 tumor suppressor protein and its
coding gene: its role in regulating the cell cycle, cell growth, cell
death and in the prevention of cancer. Recently, we have
adapted a genome-wide approach that permits the analysis
of gene networks controlled by wild type p53, as well as mu-
tant forms of p53, during malignant cell transformations
[1,2]. This approach yielded an interesting theory regarding
the gene networks that p53 downregulates. Interestingly, loss
of p53 eventually leads to the development of highly trans-
formed cells in mice. My long-range goal is to develop p53-tar-
geted cancer therapies.What does p53 do?
Early on, the general opinion was that p53 was an oncogene,
but with rather limited activity, so it was referred to as a
‘‘non-kosher’’ oncogene. But ﬁnally, in 1990, it became clear
to the ﬁeld that p53 is actually a tumor suppressor, and is
responsible for maintaining DNA integrity through an involve-
ment with DNA repair activity. The wild type p53 is a short-
lived protein that is immediately degraded following the com-
pletion of its tumor protective function. In contrast, mutant
p53 proteins are resistant to degradation, leading to their accu-
mulation in the nucleus of tumor cells. Mutant forms of p53 are
present in more than 60% of human primary tumors.How does p53 function to prevent cancer?
Wild type p53 scans for DNA damage and is critical in making
decisions to either signal the repair of the DNA damage or, if
the damage is too severe, to signal the cell to undergo apoptosis.e FederIn that sense, p53 is considered to be the ‘‘guardian’’ of the
genome and is one of the most important proteins to control
the authenticity of the genetic material. Once p53 is mutated,
this important function is lost, leading to the accumulation of
genetic alterations that contribute to the malignant cellular
transformations. One question, which is still very debatable, is
whether the mutant p53 protein, by itself, is also functional in
cells. We found that when mutant p53 was inserted into cancer
cells that are null for p53, they become resistant to apoptosis,
thereby making the cancers more resistant to chemotherapy [3].Do you have a favorite paper?
In a paper I published in 1983, I suggested that p53 should be
regarded as a speciﬁc marker for tumor cells. Since then, it has
indeed turned out to be one of the best cancer markers in the
world. This paper, although very naı¨ve, turned out to be the
most signiﬁcant in my scientiﬁc career [4].How did you balance your research with your family?
My children were born during my Ph.D. studies so I have al-
ways balanced my work and family roles. Consciously and
unhesitatingly, I spent all my free time with my children and
the rest of my time in the laboratory, since both were very
important to me. It was neither fair nor easy, but I felt that,
for me, it was deﬁnitely the right choice. I was fortunate that
my children were able to beneﬁt from the excellent education
and after-school programs provided in Israel, which allowed
me to work during the day, and be a mother in the afternoons
and evenings. An understanding husband is always critical!You said that women in science ‘do not advance at same rate as
men’. What did you mean?
It does not make sense to see that in top international scientiﬁc
meetings, only 5–10% of the scientists are female, especially
when we live in a world that is composed of equal male and fe-
male populations. The relatively low numbers of topwomen sci-
entists stems from a deeply serious societal tendency to penalize
women who want to work and also have a family. From my
point of view, any nation-wide improvement of the school sys-
tem, which could provide consistent and reliable childcare from
8 a.m. to 5 p.m., would be the most practical way to help women
scientists and would undoubtedly contribute greatly to solving
this problem. It is an unfair society in which such childcare does
not exist.Women donotwant anything that they donot deserve,
but just want to be given an equal opportunity.Contact Information
Department of Molecular Cell Biology, Weizmann Institute of
Science, Rehovot, Israel
E-mail address: varda.rotter@weizmann.ac.il
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